Despite what it sees as improvements across multiple regulatory fronts over the past few years, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) says “there still exists room for improvement” to increase the number of new drug approvals it issues ahead of any other country.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
